Aclaris Therapeutics ACRS Ratios & Valuation
| TTM Q1 '26 | TTM Q4 '25 | TTM Q3 '25 | TTM Q2 '25 | TTM Q1 '25 | ||
|---|---|---|---|---|---|---|
| Profitability | ||||||
| Gross margin | 76.3%-9.7pp | 73.3%-11.8pp | 85.6%-4.0pp | 85.8%-4.8pp | 86%-3.0pp | |
| Operating margin | -961.9%-168pp | -975.9%-218pp | -973.9%-803pp | -873.4%-663pp | -793.6%-516pp | |
| Net margin | -832.6%-100pp | -829.6%-124pp | -900%-763pp | -802%-619pp | -732.4%-484pp | |
| Returns | ||||||
| Return on equity | -48.4%+42.6pp | -50.2%+34.3pp | -113.2%-87.4pp | -101.4%-64.0pp | -91%-42.6pp | |
| Return on invested capital | -69%+55.9pp | -69.8%+41.8pp | -168.2%-123pp | -131.8%-80.9pp | -124.9%-54.2pp | |
| Efficiency | ||||||
| Asset turnover | 0×-0.1× | 0×0.0× | 0.1×0.0× | 0.1×-0.1× | 0.1×-0.1× | |
| Liquidity | ||||||
| Current ratio | 4×-1.0× | 3.4×-0.6× | 3.9×-3.1× | 3.9×-3.6× | 5.1×-1.7× | |
| Leverage | ||||||
| Debt-to-equity | 0×0.0× | 0×0.0× | 0×0.0× | 0×0.0× | 0×0.0× | |
| Per Share | ||||||
| Book value per share | $1.12-5.3% | $0.84-58.2% | $0.98-46.3% | $1.07-42.7% | $1.18-41.1% | |
| Valuation | ||||||
| Market capitalization | $685.75M+337% | $326.12M+22.9% | $205.83M+151% | $164.59M+110% | $165.47M+88.1% | |
| Price / sales | 82×+73.1× | 41.7×+27.5× | 13.1×+10.0× | 9.8×+7.4× | 9.3×+6.5× | |
| Price / book | 4.8×+3.7× | 3.2×+1.5× | 1.7×+1.1× | 1.2×+0.7× | 1.1×+0.5× |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- What are Aclaris Therapeutics's profit margins?
- Aclaris Therapeutics (ACRS) runs a 76.3% gross margin and a -961.9% operating margin, with a -832.6% net margin.
- Where do Aclaris Therapeutics's ratios come from?
- Every ratio is computed from Aclaris Therapeutics's SEC filings — trailing-twelve-month flows over period-end balances. Valuation multiples combine those fundamentals with market data, recomputed each period. Switch between quarterly, annual, and TTM, or open any ratio for its full history and peer comparisons.
